NON-SMALL CELL LUNG CANCER

This early-phase study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 changes (either too much HER2 protein or a HER2 gene mutation). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participa…

This phase 3 study tests whether a new drug called ensartinib works better than the current standard crizotinib for people with ALK-positive non-small cell lung cancer. Participants had up to one prior chemotherapy but no prior ALK-targeted treatment. The main goal is to see how …

This study looks at whether adding chemotherapy to the targeted drug osimertinib works better than osimertinib alone for people with advanced lung cancer. It includes 80 patients whose cancer still shows a specific genetic change after three weeks of osimertinib. The goal is to s…

This phase 2 trial tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy and radiation helps control non-small cell lung cancer. 43 participants received the combination therapy. The study measures tumor response and how long it takes for the cancer to pro…

This study tests a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. The study compares Ivonescimab to standard treatments and looks at how well it works and w…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants who have not received prior EGFR inhibitor treatment will take both drugs for up to 6 cycl…

This study tests a drug called taletrectinib in people with advanced lung cancer that has a specific change in the ROS1 gene. The goal is to see if the drug can shrink tumors and how safe it is. About 217 adults are taking part in this phase 2 trial.

This study tests a combination of two drugs (tuvusertib and cemiplimab) in 61 people with a type of advanced lung cancer (non-squamous non-small cell) that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if the combo can shrink tumors or slow th…

This study tests whether a combination of two drugs (datopotamab deruxtecan and rilvegostomig) can prevent lung cancer from coming back after surgery in people with stage I non-small cell lung cancer. Participants must have had their tumor completely removed and either have cance…

This study tests a precise type of radiation (SABR) for people with early-stage non-small cell lung cancer who also have interstitial lung disease, a condition that causes lung scarring. The goal is to see if this treatment can control the cancer while keeping side effects manage…

This study tests two treatments for people with advanced ALK-positive non-small cell lung cancer who haven't had treatment yet. One group gets the targeted drug brigatinib alone, the other gets brigatinib plus chemotherapy. The goal is to see if the combination helps keep the can…

This early-stage study tests an experimental drug called KIN-2787 in about 400 adults with advanced solid tumors (like lung cancer or melanoma) that have specific BRAF or NRAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug can shrink …

This study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese adults with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer that has spread. Participants must not have received prior treatment with similar drugs. The g…

This study tests a cancer-killing virus (VSV-IFNβ-NIS) combined with an immunotherapy drug (pembrolizumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective dose …

This early-phase study tests a new medicine, PF-08046032, alone and with another drug (sasanlimab) in adults with advanced lymphomas or solid tumors that have spread or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the c…

This study tests a new drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…

This early-phase trial tests a personalized treatment for adults with metastatic solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. Doctors take a person's own white blood cells, modify them in a lab to better recognize and att…

This early-phase study tests a new drug called RNDO-564, alone or with another drug (pembrolizumab), in adults with advanced solid tumors (like lung, bladder, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best …

This study tests a combination of three drugs (avutometinib, sotorasib, and defactinib) in adults with a specific genetic mutation (KRAS G12C) in non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease, both in patients who have…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. A simple blood test identifies specific genetic changes in the tumor, allowing doctors to match each patient with a drug that may work better for their cancer. The goal …

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About 44 adult…

This early-stage study tested a new drug called amivantamab, alone or with other treatments, in 751 people with advanced non-small cell lung cancer that had spread or couldn't be removed. The goal was to find the safest dose and see if the drug could shrink tumors. While not a cu…

This study tests whether giving trilaciclib before chemotherapy can prevent severe drops in white blood cells, red blood cells, and platelets in people with advanced non-small cell lung cancer. About 41 participants will receive the drug before each chemo session. The goal is to …

This study looks at people with certain cancers (like lung, breast, kidney, or melanoma) that have spread to the brain and who are also receiving immunotherapy. It compares the usual single high-dose radiation treatment to a lower dose given over several days, to see if the split…

This study follows over 2,700 cancer patients (with bladder, lung, or liver cancer) who are receiving the drug atezolizumab as part of their routine care. Researchers are tracking how long patients live and how well the drug controls their cancer, without giving any experimental …

This study tests whether a team of specialists (Molecular Tumor Board) can help choose better treatments for people with advanced non-small cell lung cancer compared to usual care. About 659 participants with stage IIb to IV lung cancer will be followed to see if expert-guided ca…

This study looks at whether a blood test that detects tumor DNA can help doctors decide when to stop immunotherapy in people with advanced melanoma or lung cancer. About 39 patients who have been on immunotherapy for at least a year and show good response will be followed. The go…

This study looks at people with suspected or confirmed non-small cell lung cancer who need a tissue sample for genetic testing. It compares taking 2 versus 3 samples from each lymph node during an ultrasound-guided biopsy to see if fewer samples still provide enough material. All…

This study compares two minimally invasive surgeries for early-stage lung cancer: robotic-assisted and video-assisted (VATS). It aims to see which one gives patients a better quality of life after recovery and which is more cost-effective for the healthcare system. About 446 adul…

This study looks at how doctors use a blood test called VeriStrat to decide treatments for people with non-small cell lung cancer. About 5,000 patients are being observed to see if the test results change treatment plans and improve outcomes. The goal is to learn how to better ma…

This study looks back at how patients with non-small-cell lung cancer that has spread only to a few spots in the brain were treated. The goal is to see which treatment strategies worked best. About 46 adults from one hospital are included. The study does not test a new treatment …